NeuroMab™ Anti-TDP43 BBB Shuttle Antibody(NRZP-1022-ZP2635)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Immunogen

full length TDP-43 (FL TDP-43)

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

WB; IHC; ELISA; In Vitro; In Vivo

Relevant Diseases

Amyotrophic Lateral Sclerosis

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

TDP43

Official Name

TDP-43

Full Name

TAR DNA binding protein

Alternative Names

TDP-43; TAR DNA binding protein

Product Pictures

ELISA

Fig.4 Quantification of TDP-43 levels in CSF of various FTLD-TDP patients versus healthy controls with AlphaLISA assay with ACI-7069-633B12-AM (IgG2a variant) and ACI-7071-809F12- Abl (IgG2a variant).

Endpoints after 30h were normalized to isotype control (grey bar) and % aggregated TDP-43 was calculated for ACI-7069- 633B12-AM (dotted grey bar). Mean values ± SD are shown for three independent experiments and statistical differences between isotype control and ACI-7069-633B12-AM (IgG2a variant) were analyzed by Welch's t-tests (***p < 0.001).

ELISA

Fig.1 Quantification of TDP-43 levels in CSF of various FTLD-TDP patients versus healthy controls with AlphaLISA assay with ACI-7069-633B12-AM (IgG2a variant) and ACI-7071-809F12- Abl (IgG2a variant).

Publications